Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review

被引:21
|
作者
Dragoman, Monica V. [1 ]
Simmons, Katharine B. [2 ,3 ]
Paulen, Melissa E. [4 ]
Curtis, Kathryn M. [2 ]
机构
[1] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland
[2] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA
[3] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA
[4] Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46204 USA
关键词
Combined hormonal contraception; Obesity; Contraceptive effectiveness; Oral contraception; BODY-MASS INDEX; NATIONAL-SURVEY; FAILURE; WEIGHT; EFFICACY; COHORT; RISK;
D O I
10.1016/j.contraception.2016.10.010
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate from the literature whether combined hormonal contraception (CHC), including combined oral contraception pills (COCs), transdermal patch, vaginal ring or combined injectables, have different effectiveness or failure rates by body weight or body mass index (BMI). Study design: We searched PubMed and the Cochrane Library databases for all articles in all languages published between inception and February 2016, for evidence relevant to body weight or BMI, CHC use and contraceptive effectiveness. The quality of each individual study was assessed using the system for evaluating evidence developed by the United States Preventive Services Task Force. Results: From 2874 articles, we identified 15 reports for inclusion, all of fair to poor quality. Fourteen studies measured the association of obesity status and contraceptive failure among COC users. Three fair quality and one poor quality study reported increased COC failure among a heterogeneous population of overweight and obese women compared with normal weight women, while eight fair quality and two poor quality studies did not find an association. Two fair quality studies reported on contraceptive transdermal patches. One pooled analysis described a higher proportion of pregnancies among women using the patch who weighed >= 90 kg; another secondary analysis suggested BMI>30 was associated with increased failure. No studies directly compared contraceptive effectiveness using the combined vaginal ring or combined injectable. Conclusion: Current available evidence addressing the risk of CHC failure in obese compared to normal weight women is limited to fair and poor quality studies. Studies of COCs show mixed results, though absolute differences in COC failure by body weight and BMI are small. Based on limited evidence, it appears that increasing body weight and BMI may contribute to decreasing contraceptive patch effectiveness. (C) 2017 Published by Elsevier Inc.
引用
收藏
页码:117 / 129
页数:13
相关论文
共 50 条
  • [21] Progestogen-only contraceptive use in obese women
    Curtis, Kathryn M.
    Ravi, Anita
    Gaffield, Mary Lyn
    CONTRACEPTION, 2009, 80 (04) : 346 - 354
  • [22] Contraceptive Care of Obese Women
    Morse, Jessica Elizabeth
    Pathak, Prutha Rohit
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (01) : 56 - 66
  • [23] Hormonal Contraceptive Use and Discontinuation Among HIV-Infected Women in Uganda and Zimbabwe
    Bengtson, Angela
    Kwok, Cynthia
    Salata, Robert A.
    Byamugisha, Josaphat
    Chipato, Tsungai
    Rwambuya, Sandra
    Moyo, Precious
    Morrison, Charles S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (04) : 506 - 513
  • [24] Pharmacokinetics of the etonogestrel contraceptive implant in obese women
    Mornar, Sara
    Chan, Lingtak-Neander
    Mistretta, Stephanie
    Neustadt, Amy
    Martins, Summer
    Gilliam, Melissa
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (02) : 110.e1 - 110.e6
  • [25] Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women
    Cheang, Kai I.
    Essah, Paulina A.
    Sharma, Susmeeta
    Wickham, Edmond P., III
    Nestler, John E.
    FERTILITY AND STERILITY, 2011, 96 (02) : 353 - U409
  • [26] Contraceptive knowledge and use among women with intellectual, physical, or sensory disabilities: A systematic review
    Horner-Johnson, Willi
    Moe, Esther L.
    Stoner, Ryan C.
    Klein, Krystal A.
    Edelman, Alison B.
    Eden, Karen B.
    Andresen, Elena M.
    Caughey, Aaron B.
    Guise, Jeanne-Marie
    DISABILITY AND HEALTH JOURNAL, 2019, 12 (02) : 139 - 154
  • [27] Hormonal Contraceptive Use and HIV Disease Progression Among Women in Uganda and Zimbabwe
    Morrison, Charles S.
    Chen, Pai-Lien
    Nankya, Immaculate
    Rinaldi, Anne
    Van Der Pol, Barbara
    Ma, Yun-Rong
    Chipato, Tsungai
    Mugerwa, Roy
    Dunbar, Megan
    Arts, Eric
    Salata, Robert A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (02) : 157 - 164
  • [28] Phamiacokinetics of a combined oral contraceptive in obese and normal-weight women
    Westhoff, Carolyn L.
    Torgal, Anupama H.
    Mayeda, Elizabeth R.
    Pike, Malcolm C.
    Stanczyk, Frank Z.
    CONTRACEPTION, 2010, 81 (06) : 474 - 480
  • [29] The use of hormonal contraceptive agents and mood disorders in women
    Svendal, Gjertrud
    Berk, Michael
    Pasco, Julie A.
    Jacka, Felice N.
    Lund, Anders
    Williams, Lana J.
    JOURNAL OF AFFECTIVE DISORDERS, 2012, 140 (01) : 92 - 96
  • [30] Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History
    Grandi, Giovanni
    Toss, Angela
    Cagnacci, Angelo
    Marcheselli, Luigi
    Pavesi, Silvia
    Facchinetti, Fabio
    Cascinu, Stefano
    Cortesi, Laura
    CLINICAL BREAST CANCER, 2018, 18 (01) : E15 - E24